Biotime, Inc. Announces the Resignation of Cavan Redmond from Board of Directors
July 05, 2019 at 09:05 pm
Share
BioTime, Inc. on June 14, 2019, Cavan Redmond previously informed the Board of Directors of the Company (the "Board") on June 11, 2019 that he had decided not to stand for reelection as a director at the 2019 annual meeting of shareholders of the Company to be held on July 30, 2019. On July 2, 2019, Mr. Redmond informed the Chairman of the Board and Chief Executive Officer of the Company that he would be resigning from the Board effective immediately. Mr. Redmond's decision to resign at this time was not because of a disagreement with the Company on any matter relating to the Company's operations, policies, or practices.
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs. The Companyâs programs are based on its cell-based technology platform and associated development and manufacturing capabilities. From this platform, the Company designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions. Its neuroscience focused pipeline includes OpRegen, a retinal pigment epithelial cell therapy in phase II a development, for the treatment of geographic atrophy secondary to age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy in phase I/II a development for the treatment of spinal cord injuries; ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and RND1.